Ipamorelin Peptide Research
Ipamorelin is one of the best-known selective GH secretagogues in the peptide space.
gh-secretagogue
Clinical
research maturity
Overview
Ipamorelin is one of the best-known selective GH secretagogues in the peptide space. It is generally positioned as a ghrelin-receptor agonist with a cleaner and more selective growth-hormone release profile than older GHRPs.
Related stacks
Apex Stack
Performance Stack
GH Optimization Stack
Mechanism
It acts at the ghrelin receptor to stimulate pulsatile GH release. The practical appeal is the idea of endogenous GH support without direct GH replacement, often with fewer off-target endocrine effects than older secretagogues in theory.
Clinical interest
Clinical interest centers on hormone optimization, recovery, body composition, and GH-axis support. It is often used as the comparator benchmark for other secretagogues such as hexarelin and sermorelin-based protocols.
Research summary
The literature includes human pituitary testing, GH-secretagogue biology reviews, and broader endocrine comparisons. The evidence supports real GH stimulation, but not the kind of long-term body-composition outcomes seen with approved obesity or GH-deficiency drugs.
Safety considerations
Concerns include fluid retention, headache, altered glucose handling, and inappropriate use in people with contraindications to GH-axis stimulation. Product quality and overstatement of results are common practical risks.
Key information
Research stage
Clinical
Evidence rating
Moderate
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
6
)
Frequently asked questions
What is ipamorelin?
Ipamorelin is a ghrelin-receptor agonist peptide designed to stimulate endogenous growth-hormone release in a relatively selective manner.
Is ipamorelin the same as sermorelin?
No. Ipamorelin works through the ghrelin receptor, while sermorelin is a GHRH analog that stimulates the pituitary through a different upstream pathway.